Table 3

Example of the REMARK profile illustrated using data from a study of expression of epithelial membrane protein-2 in patients with endometrial adenocarcinoma [158].

a) Patients, treatment and variables


136 Patients with endometrial adenocarcinoma assessed for eligibility, 37 excluded (33 no informative immune histochemistry, 4 without clinical information)

99 Patients included, stages IA to IVB

Formalin fixed, paraffin embedded endometrial tissue samples, Department of Pathology, UCLA Los Angeles, USA


Marker (and how was the marker handled in analysis?)

M = epithelial membrane protein-2

Immunoreactive score obtained by multiplying subscores for intensity (0 to 3+) and distribution of immunoreactivity (0 to 4+) grouped as negative (score 0), weak (1 to 3) or moderate-to-strong (4 to 12)

Outcomes:

DFS (97 patients, 42 events), OS (99 patients, 32 events)

Further variables:

v1 = age, v2 = ER, v3 = PR, v4 = vascular invasion, v5 = stage, v6 = histology, v7 = grade


b) Statistical analyses of survival outcomes


DFS

OS

Aim

Patients

Events

Patients

Events

Variables considered

Results/remarks


A1: Univariable

97

42

99

32

M, v1-v7

Figure 3, Figure 4, Table 2, Table 3

DFS: except v1 all significant

OS: all significant

A2: Multivariable

97

42

99

32

DFS: M, v2-v7

Table 4, Table 5

OS: M, v1-v7

In multivariable analysis: all significant in A1, then stepwise selection

Variables in final models: DFS: M, v5, v6; OS: v4, v6, v7 (M is not included)


DFS: disease-free survival; ER: estrogen receptor; M: epithelial protein; PR: progesterone receptor; OS: overall survival.

Altman et al. BMC Medicine 2012 10:51   doi:10.1186/1741-7015-10-51

Open Data